# First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

> **NCT01554085** · PHASE1 · TERMINATED · sponsor: **Alios Biopharma Inc.** · enrollment: 78 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** ALS-002158
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01554085
- **Lead sponsor:** Alios Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12-31
- **Primary completion:** 2012-09-30
- **Final completion:** 2012-09-30
- **Target enrollment:** 78 (ACTUAL)
- **Why stopped:** ALS-2158 showed insufficient antiviral activity to warrant proceeding with further clinical development.
- **Last updated:** 2017-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01554085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01554085, "First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01554085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*